On February 17, 2026, MIG Capital disclosed a decrease in its holdings. Sotera Health (NASDAQ:SHC)2,262,292 shares were sold. The estimated transaction value, based on quarterly average prices, is $37.41 million.
According to one SEC Filings Dated February 17, 2026, MIG Capital decreased its stake in Sutera Health by 2,262,292 shares during the fourth quarter of 2025. At the end of the quarter, total position value decreased by $31.83 million, a figure that includes changes in trading and share prices.
It was a sale transaction, giving Sutera Health 5.88% of MIG Capital’s 13F assets under management.
Top Holdings After Filing:
NASDAQ:META: $52.45 million (8.9% of AUM)
NASDAQ:DXCM: $40.19 million (6.8% AUM)
NASDAQ:SHC: $34.65 million (5.9% of AUM)
NASDAQ:MSFT: $34.25 million (5.8% of AUM)
NASDAQ: CELH: $33.93 million (5.8% of AUM)
As of Friday, Sutera Health shares were trading at $13.41, up 18% over the past year, slightly outpacing the S&P 500’s roughly 20% gain over the same period.
Matric | value |
|---|---|
Price (as of Friday) | $13.41 |
Market capitalization | $3.8 billion |
Revenue (TTM) | $1.16 billion |
Net Income (TTM) | $77.95 million |
Sotera Health provides sterilization services (gamma, electron beam, EO processing), lab testing, and consulting solutions for the medical device, pharmaceutical, and food industries.
The firm operates a service-based business model that generates revenue through sterilization, laboratory testing, and consulting for regulated industries.
It serves medical device manufacturers, pharmaceutical companies, and food/agricultural producers in North America, Europe, and globally.
Sotera Health is a leading provider of sterilization and laboratory services, supporting critical supply chains in healthcare, pharmaceuticals and food safety. The company leverages a diverse portfolio of sterilization technologies and testing capabilities to serve highly regulated industries. Its scale, technical expertise, and global reach provide a competitive advantage in ensuring safety and compliance for its customers.
Sotera continues to scale while maintaining strong profitability, and posted its 20th consecutive year of revenue growth. In 2025, the sale went up 5.7% to $1.16 billion, while adjusted EBITDA increased 8.2% to approximately $594 million, reflecting solid operating leverage in its Sterigenics sterilization business and related testing services. Meanwhile, net income nearly doubled from last year to $78 million, showing meaningful progress on the bottom line.
Despite trimming its position, the holding still represents about 6% of portfolio assets, putting it among the fund’s largest positions with companies such as Meta, Dexcom, and Microsoft. This suggests that the move may simply be routine portfolio management rather than reflecting a dramatic change in punishment. It’s also important to note that shares are down about 24% this year, and the one-year gains were significantly higher than before. With that in mind, the MIG might just have taken advantage.
So what does this mean for investors looking at Sutera? Ultimately, the company expects another year of growth, estimating revenue growth of between 5% and 6.5% in 2026, and EBITDA growth of between 5.5% and 7%. If it delivers, it makes sense why a fund like MIG would maintain a meaningful position.